ArticleOpen forum infectious diseases2020
Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19.
Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 3 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Comparing the clinical characteristics and outcomes of COVID-19-associate pulmonary aspergillosis (CAPA): a systematic review and meta-analysis.Infection · 2022Pooled it
- Incidence and mortality of COVID-19-associated pulmonary aspergillosis: A systematic review and meta-analysis.Mycoses · 2021Pooled it
- Invasive mould disease in fatal COVID-19: a systematic review of autopsies.The Lancet. Microbe · 2021Pooled it
- Milky Tea-Colored Pleural Effusion: Empyema Complicated by Pneumothorax Due to Mixed Infection With Mycobacterium tuberculosis and Aspergillus fumigatus.The American journal of case reports · 2026Article
- Pathogen-specific IgE-reactive cytosolic allergenic epitopes of Aspergillus fumigatus for immunodiagnostic/immunotherapeutic applications against allergic aspergillosis.Annals of clinical microbiology and antimicrobials · 2026Article
- Acute Respiratory Distress Syndrome Due to COVID-19-Associated Pulmonary Aspergillosis with Rare Extensive Tracheobronchial Pseudomembranous Involvement: A Case Report.Mycopathologia · 2025Article
- COVID-19-associated Pulmonary Aspergillosis in Mechanically Ventilated Patients at 7 US Hospitals: Epidemiology and Estimated Likelihood of Invasive Pulmonary Aspergillosis-Results of the Prospective MSG-017 Study.Open forum infectious diseases · 2025Article
- An Observational Cohort Study of Bronchoalveolar Lavage Fluid Galactomannan andOpen forum infectious diseases · 2025Article
- Follow-up of Surgical and Nonsurgical Patients With Pulmonary Aspergillosis: A Real-World Study.Infection and drug resistance · 2025Article
- Key sugar transporters drive development and pathogenicity inFrontiers in cellular and infection microbiology · 2025Article
- Clinical characteristics and prognosis of COVID-19- associated invasive pulmonary aspergillosis in critically patients: a single-center study.Frontiers in cellular and infection microbiology · 2025Article
- Study protocol: A randomized, double-blind, placebo-controlled trial of isavuconazole prophylaxis for the prevention of covid-19-associated pulmonary aspergillosis.Contemporary clinical trials communications · 2024Article
- Mixed Aspergillosis and Mucormycosis Infections in Patients with COVID-19: Case Series and Literature Review.Mycopathologia · 2024Review
- Mortality in ICU Patients with COVID-19-Associated Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2023Review
- Characterization of Aspergillus spp. isolated from patients with coronavirus disease 2019.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2023Article
- Invasive Pulmonary Aspergillosis in Coronavirus Disease 2019 Patients Lights and Shadows in the Current Landscape.Advances in respiratory medicine · 2023Review
- Surrogate infection model predicts optimal alveolar macrophage number for clearance of Aspergillus fumigatus infections.NPJ systems biology and applications · 2023Article
- Race and ethnicity: Risk factors for fungal infections?PLoS pathogens · 2023Review
- A Rare Case of MandibularDentistry journal · 2022Article
- Global Emergence of Resistance to Fluconazole and Voriconazole inOpen forum infectious diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary aspergillosis has been increasingly reported following severe respiratory viral infections. Millions have been infected by SARS-CoV-2, placing large numbers of patients at-risk for COVID-19 associated pulmonary aspergillosis (CAPA). Prompt recognition of this syndrome and is paramount to improve outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.